Clark J A, Pasternak G W
Cotzias Laboratory of Neuro-Oncology Memorial Sloan-Kettering Cancer Center.
Neuropharmacology. 1988 Mar;27(3):331-2. doi: 10.1016/0028-3908(88)90052-4.
Although a number of potent kappa ligands have been reported, virtually all also label mu receptors with very high affinity. In contrast, we found that U50,488 is highly selective for kappa sites (Ki 12 nM) when compared to both morphine-selective (mu2) or delta receptors (both Ki values greater than 500 nM) confirming earlier reports. However, these reports did not examine interactions with mu1 receptors. In marked distinction to all other kappa-active agents examined which typically compete mu1 binding with Ki values under 1 nM, U50,488 competed mu1 binding quite poorly (Ki 370 nM). Thus, U50,488 is a highly selective kappa agent with very poor affinity for both subtypes of mu and delta receptors.
尽管已经报道了许多强效κ配体,但实际上所有这些配体也都以非常高的亲和力标记μ受体。相比之下,我们发现与吗啡选择性(μ2)或δ受体(两者的Ki值均大于500 nM)相比,U50,488对κ位点具有高度选择性(Ki为12 nM),这证实了早期的报道。然而,这些报道并未研究其与μ1受体的相互作用。与所有其他所研究的典型κ活性药物不同,其他药物通常以低于1 nM的Ki值竞争μ1结合,而U50,488竞争μ1结合的能力相当差(Ki为370 nM)。因此,U50,488是一种对μ和δ受体的两种亚型亲和力都非常低的高度选择性κ药物。